Bosutinib in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase After Frontline TKI Failure

Clinical trial NCT02906696 · TERMINATED

Trial details

NCT number: NCT02906696
Sponsor: M.D. Anderson Cancer Center
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Blasts Under 15 Percent of Bone Marrow Nucleated Cells Blasts Under 15 Percent of Peripheral Blood White Cells Blasts Under 30 Percent of Bone Marrow Nucleated Cells Blasts Under 30 Percent of Peripheral Blood White Cells Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Start date: 2016-10-28
Primary completion: 2019-08-08
Enrollment: 8

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.